Overview
Samson Chan is an experienced Hong Kong corporate lawyer, advising issuers, sponsors, underwriters and financial institutions across the full spectrum of Hong Kong equity capital market transactions including IPOs, pre-IPO investment, post-IPO equity financing, M&A and corporate matters.
Samson has particular expertise in listings for “New Economy” clients — technology, energy and healthcare companies, including pre-revenue biotech issuers, specialist technology companies and businesses with weighted voting rights (WVR) or variable interest entity (VIE) structures. He also advises on secondary listings and spin-off listings.
Recognised as a Notable Practitioner in China equity capital markets by IFLR for five consecutive years (2019–2024), Samson brings deep market knowledge and a practical, client-focused approach to some of Hong Kong's most complex transactions.
Experience
Samson’s experience highlights include advising on:
- Landmark HK IPOs: Contemporary Amperex Technology Co Ltd (the second-largest IPO globally and the largest in Hong Kong in 2025), Sanhua Intelligent and Chery Auto (both among the top 10 largest HK IPOs in 2025), and Wuxi Lead Intelligent Equipment (world’s largest lithium-ion battery equipment maker)
- Other Notable HK IPOs, secondary listing and listing by way of introduction including:
- TMT and consumer: Chifeng Gold, JD.com, Bilibili, JST Group, Chenqi Technology (also known as Ruqi Mobility), Kanzhun (also known as BOSS Zhipin), Shanghai Chicmax Cosmetic, Ping An OneConnect Financial Technology, XD Inc., Weimob, iDreamSky Technology, China Literature, Ping An Healthcare and Technology (also known as Ping An Good Doctor).
- Healthcare and biotech: SciClone Pharmaceuticals, Sirnaomics, Lepu Biopharma, Harbour BioMed o Industrial and others: CIMC Vehicles, Inner Mongolia Energy Engineering, Bank of Jiujiang, China Kepei Education and Virscend Education.*
- Issuance and M&A transactions in the TMT, healthcare, consumer and other sectors including BOCOM on its RMB120 billion share issuance, SciClone Pharmaceuticals on its privatisation by GL Capital, Tencent on its HK$3.3bn subscription in Meituan, JF SmartInvest on its acquisition of Hong Kong securities firms, China Literature on the RMB 15.5bn acquisition of New Classics Media, Actis on its disposal of investment in Jiashili Group and Red Star Macalline on the sale of 29.95% equity interests by the controlling shareholder to Xiamen C&D Inc.*
*Denotes experience from previous firms
Admissions